Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

(2021) M. Cabezón et al.   Clinical Epigenetics

DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia

(2021) Brian Giacopelli et al.   GENOME RESEARCH

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

(2020) Courtney D DiNardo et al.   Lancet Haematology

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

(2019) R. F. Schlenk et al.   LEUKEMIA

Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML

(2019) Chenchen Zhao et al.   BRITISH JOURNAL OF HAEMATOLOGY

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia

(2017) Niloufer Khan et al.   LEUKEMIA & LYMPHOMA

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

(2016) Aziz Nazha et al.   LEUKEMIA RESEARCH

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

(2016) Sheng Li et al.   NATURE MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

(2016) Koichi Takahashi et al.   Oncotarget

An update of current treatments for adult acute myeloid leukemia

(2015) H. Dombret et al.   BLOOD

Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia

(2015) Kristen Meldi et al.   JOURNAL OF CLINICAL INVESTIGATION

Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides

(2015) A M Zeidan et al.   LEUKEMIA

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predicting response to epigenetic therapy

(2014) Marianne B. Treppendahl et al.   JOURNAL OF CLINICAL INVESTIGATION

Comprehensive analysis of DNA methylation data with RnBeads

(2014) Yassen Assenov et al.   NATURE METHODS

Epigenetics Meets Genetics in Acute Myeloid Leukemia: Clinical Impact of a Novel Seven-Gene Score

(2013) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Origins of aberrant DNA methylation in acute myeloid leukemia

(2013) T Schoofs et al.   LEUKEMIA

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

(2013) Bhavana Bhatnagar et al.   LEUKEMIA & LYMPHOMA

Low-level processing of Illumina Infinium DNA Methylation BeadArrays

(2013) Timothy J. Triche et al.   NUCLEIC ACIDS RESEARCH

DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes

(2013) Dvir Aran et al.   GENOME BIOLOGY

A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data

(2012) Andrew E. Teschendorff et al.   BIOINFORMATICS

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

(2012) Ellen K. Ritchie et al.   LEUKEMIA & LYMPHOMA

Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation

(2012) Davis J. McCarthy et al.   NUCLEIC ACIDS RESEARCH

MDS: Refining existing therapy through improved biologic insights

(2011) Jordan Schecter et al.   BLOOD REVIEWS

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

(2010) R. Itzykson et al.   BLOOD

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

(2010) Maria E. Figueroa et al.   CANCER CELL

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies

(2009) T. E. Fandy et al.   BLOOD

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS

(2009) M. Y. Follo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Next-Generation DNA Sequencing Methods

(2008) Elaine R. Mardis   Annual Review of Genomics and Human Genetics